{"id":542756,"date":"2021-05-11T18:28:01","date_gmt":"2021-05-11T18:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542756"},"modified":"2021-05-11T18:28:01","modified_gmt":"2021-05-11T18:28:01","slug":"car-tcell-therapy-for-nonhodgkins-lymphoma-nhl-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/car-tcell-therapy-for-nonhodgkins-lymphoma-nhl-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_542756.html","title":{"rendered":"CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight"},"content":{"rendered":"
\"CAR<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cCAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)\u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL), historical and forecasted epidemiology as well as the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)- Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

DelveInsight’s<\/span> “CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)– Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″<\/span> report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL), historical and forecasted epidemiology as well as the  CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    Market Size of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma in the 6MM is expected to be USD 2796.2 Million in 2030<\/span><\/p>\n<\/li>\n

  2. \n

    Of the emerging therapies, the most anticipated products to get launched are JCAR017 (Celgene’s, (a BMS company) ), KTE-X19  (Gilead). Some of these products have also received Fastrack Designations and Orphan Designations.<\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report covers a descriptive overview and comprehensive insight of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) epidemiology and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span><\/p>\n

    4.The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market.<\/span><\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market<\/span><\/a><\/strong><\/p>\n

    CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL): Overview<\/strong><\/p>\n

    CAR T-cell therapy is a promising treatment for some patients with non-Hodgkin lymphoma (NHL) that has relapsed or has not responded to other therapies (refractory). It is a highly specialized therapy that involves genetically modifying a patient’s own T cells to attack their cancer.<\/span><\/p>\n

    The key players involved in CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market:<\/strong><\/p>\n

      \n
    1. \n

      Gilead Sciences<\/span><\/p>\n<\/li>\n

    2. \n

      Celgene Corporation (a BMS company)<\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        KTE-X19<\/span><\/p>\n<\/li>\n

      2. \n

        JCAR017<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1.Report Introduction<\/span><\/p>\n

        2.Executive Summary<\/span><\/p>\n

        3.SWOT analysis<\/span><\/p>\n

        4.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Overview at a Glance<\/span><\/p>\n

        6.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Disease Background and Overview<\/span><\/p>\n

        7.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Epidemiology and Patient Population<\/span><\/p>\n

        8.Country-Specific Patient Population of  CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)<\/span><\/p>\n

        9.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Current Treatment and Medical Practices<\/span><\/p>\n

        10.Unmet Needs<\/span><\/p>\n

        11.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Emerging Therapies<\/span><\/p>\n

        12.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Outlook<\/span><\/p>\n

        13.Country-Wise  CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Analysis (2017–2030)<\/span><\/p>\n

        14.Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15.Market drivers<\/span><\/p>\n

        16.Market barriers<\/span><\/p>\n

        17.Appendix<\/span><\/p>\n

        18.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Report Methodology<\/span><\/p>\n

        19.DelveInsight Capabilities<\/span><\/p>\n

        20.Disclaimer<\/span><\/p>\n

        21.About DelveInsight<\/span><\/p>\n

        Related Reports:<\/strong><\/p>\n

        CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma- Pipeline Insight, 2021<\/strong><\/p>\n

        “<\/span>CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma – Pipeline Insight, 2021<\/strong>” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market. A detailed picture of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) pipeline landscape is provided, which includes the disease overview and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) treatment guidelines.<\/span><\/p>\n

         <\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cCAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)\u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL), historical and forecasted epidemiology as well as the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542756","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542756"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542756\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}